Neoplasms

All Conditions

Nervous System Diseases

Gland and Hormone Related Diseases

Eye Diseases

Symptoms and General Pathology

Adenoma

Pituitary Diseases

Vision, Low

Pituitary Neoplasms

Vision Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Endocrine System Diseases

Sensation Disorders

Neurologic Manifestations

Endocrine Gland Neoplasms

Hypothalamic Neoplasms

Supratentorial Neoplasms

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Optical Coherence Tomography Angiography without surgery

Optical Coherence Tomography Angiography before and after neurosurgery

Neurosurgery

ARNAUD MARTEL

The aim of the study is to assess accurancy of OCT angiography as a pronostic marker for patients undergoing neurosurgery for compressiver macroadenoma as compared with visual acuity, visual field and OCT.

OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.

visual field evolution assessed by Middle deviation

visual field evolution assessed by visual function index

Centre Hospitalier Universitaire de Nice

Heart and Blood Diseases

Nutritional and Metabolic Diseases

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Musculoskeletal Diseases

Diseases and Abnormalities at or Before Birth

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Coronary Artery Disease

Stroke

Diabetes Mellitus

Diabetic Foot

Lung Diseases

Ear Diseases

Joint Diseases

Congenital Abnormalities

Pneumonia

Coronary Disease

Myocardial Ischemia

Lung Diseases, Interstitial

Ulcer

Foot Ulcer

Kidney Calculi

Calculi

Nephrolithiasis

Hyperaldosteronism

Adrenocortical Adenoma

Labyrinth Diseases

Labyrinthitis

Intracranial Arteriovenous Malformations

Arteriovenous Malformations

Ischemia

Heart Diseases

Arteriosclerosis

Arterial Occlusive Diseases

Vascular Diseases

Respiratory Tract Diseases

Diabetic Angiopathies

Leg Ulcer

Skin Ulcer

Skin Diseases

Diabetes Complications

Diabetic Neuropathies

Foot Diseases

Kidney Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urolithiasis

Urinary Calculi

Male Urogenital Diseases

Pathological Conditions, Anatomical

Vascular Malformations

Cardiovascular Abnormalities

Adrenocortical Hyperfunction

Adrenal Gland Diseases

Otorhinolaryngologic Diseases

Adrenal Cortex Neoplasms

Adrenal Gland Neoplasms

Adrenal Cortex Diseases

Otitis

Cerebrovascular Disorders

Central Nervous System Vascular Malformations

Nervous System Malformations

Intracranial Arterial Diseases

Adenoma of the Adrenal Gland

Intracranial Arteriovenous Malformation

Hyperadrenalism

Micronutrients

All Drugs and Chemicals

Zinc

Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.

For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:

* Tube potential 120 kVp;
* Tube current time product of 150 mAs;
* Gantry revolution time 0.33 s;
* Automatic exposure control (angular and longitudinal) combined xyz-axis;
* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;

Spectral Photon Counting Computed Tomography (SPCCT)

The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:

* Base platform : iCT scanner
* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp
* Tube current (mA) : 10 - 300
* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm
* Z-coverage isocenter (mm) : 20 mm
* FOV (mm) : 500
* Minimum rotation time : 0.33 s/rotation
* Acquisition modes : Axial, Helical, Step \& Shoot

DECT (Dual Energy CT)

Philippe DOUEK, Pr

Adeline MANSUY

This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection.

Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive and representative results of the improvement in image quality between SPCCT and DECT that will be performed CT imaging on several body regions and structures, including diabetic foot, diabetic calcium coronary scoring, adrenal glands, coronary arteries, lung parenchyma, kidney stones, inner ear, brain and joints, earl/temporal bone, colorectal carcinosis.

Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)

A single four-point scale will be used (1: unacceptable, 2: usable under limited conditions, 3: probably acceptable, 4: fully acceptable) based on the European guidelines on quality criteria for computed tomography

The diagnostic confidence grade will be calculated on a four-point scale (1: insufficient, 2: poor, 3: average, 4: good).

It will be calculated on a five-point scale (1: poor, 2: fair, 3: average, 4: good, 5: excellent) for each following criterion: noise, artifacts and sharpness.

To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

The CTDI is an estimation of the dose delivered to the organs for each acquired section that is based on acquisition parameters of a water phantom with a 32 cm diameter. The value is expressed in milligray (mGy).

To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

The DLP is obtained as follows: CTDI \* length of body explored = value in mGy.cm.

To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

The equivalent dose is obtained by multiplying the DLP to the specific organ conversion factor.

The noise by selecting regions of interest (ROI) will calculated.

The density (HU) by selecting regions of interest (ROI) will calculated.

The contrast-to-noise ratio (CNR) by selecting regions of interest (ROI) will calculated.

Depiction of anatomical structures of interest will be graded on a four-point scale (1: visualization just possible, 2: unclear borders but different structures already visible, 3: very good visualization, well-defined anatomy, 4: perfect delineation of anatomy).

An average radiation dose delivered to the patients for each clinical application will be calculated.

Statistical comparison between SPCCT and DECT will be performed over all images and anatomical structures globally and also for each clinical application of interest.

Hospices Civils de Lyon

Acromegaly

Bone Diseases

Bone Diseases, Endocrine

Hypoglycemic Agents

Antineoplastic Agents

Gastrointestinal Agents

Insulin

Insulin, Globin Zinc

Hormones

Somatostatin

Mitogens

Octreotide

Antineoplastic Agents, Hormonal

Sandostatin LAR Depot versus transsphenoidal surgery

The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas. The primary goal is to normalize insulin-like growth factor-1 (IGF-1) levels. Secondary goals are to compare Sandostatin LAR® (Registered Trademark) Depot treatment and transsphenoidal surgery to achieve the following goals: suppress growth hormone levels to less than or equal to 2.5 ng/mL, relieve the clinical signs and symptoms of acromegaly, reduce the size of the macroadenomas, produce few side effects, assess the prognostic value of baseline pituitary adenoma size, extension and baseline growth hormone level on post-treatment growth hormone and IGF-1 levels, and assess the resource utilization of each treatment type.

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.	NCT04074642	Pituitary Adeno...	Neurosurgery	18 Years -	Centre Hospitalier Universitaire de Nice
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)	NCT04328181	Diabetic Foot U... Coronary Artery... Parenchymatous;... Kidney Stone Inner Ear Disea... Brain Stroke Joint Diseases Diabetes Adrenal Inciden... Hyperaldosteron... Macroadenoma Interstitial Lu... Intracranial Ar...	Spectral Photon... DECT (Dual Ener...	18 Years -	Hospices Civils de Lyon
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly	NCT00001860	Acromegaly Pituitary Neopl...	Sandostatin LAR...	-	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for macroadenoma

Every month we try and update this database with for macroadenoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.